Castleman's disease: From basic mechanisms to molecular therapeutics

Oncologist

Volumn 16, Issue 4, 2011, Pages 497-511

  El Osta, Hazem E ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Castleman's disease; Human herpes virus 8; Interleukin 1; Interleukin 6; Molecular therapeutics; Targeted therapy

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CIMETIDINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; IFOSFAMIDE; INTERFERON; MELPHALAN; MESNA; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SURAMIN; THALIDOMIDE; TOCILIZUMAB; UNINDEXED DRUG; VALGANCICLOVIR; VINBLASTINE; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KAPOSI SARCOMA; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REMISSION; RHEUMATOID ARTHRITIS; SKIN DEFECT; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIVIRAL AGENTS; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HUMANS; INTERLEUKIN-6; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 79955556128     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0212     Document Type: Article

References (109)

1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954;251:396-400.
2. Casper C. The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol 2005; 129:3-17.
3. Dupin N, Diss TL, Kellam P et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-1412.
4. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007;14: 354-359.
5. Larroche C, Cacoub P, Godeau P. [Castleman's disease]. Rev Med Interne 1996;17:1003-1013.
6. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698-704.
7. Nasti G, Talamini R, Antinori A et al. AIDS-related Kaposi's sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003;21:2876-2882.
8. Powles T, Stebbing J, Bazeos A et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009;20:775-779.
9. Oksenhendler E, Duarte M, Soulier J et al. Multicentric Castleman's disease in HIV infection: A clinical and pathological study of 20 patients. AIDS 1996;10:61-67.
10. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-626.
11. Vinzio S, Ciarloni L, Schlienger JL et al. Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? Eur J Intern Med 2008;19:367-369.
12. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer 2007;110:1911-1928.
13. Brandt SJ, Bodine DM, Dunbar CE et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-599.
14. Katsume A, Saito H, Yamada Y et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-311.
15. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-1367.
16. Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
17. Sullivan RJ, Pantanowitz L, Casper C et al. HIV/AIDS: Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008;47:1209-1215.
18. Soulier J, Grollet L, Oksenhendler E et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-1280.
19. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6:1121-1127.
20. Friborg J Jr, Kong W, Hottiger MO et al. P53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-894.
21. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol 2006;18:456-462.
22. Field N, Low W, Daniels M et al. KSHV vFLIP binds to IKK to activate IKK. J Cell Sci 2003;116:3721-3728.
23. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NFB activation. J Biol Chem 2003;278:52437-52445.
24. Neipel F, Albrecht JC, Ensser A et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997;71:839-842.
25. Adam N, Rabe B, Suthaus J et al. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol 2009;83:5117-5126.
26. Aoki Y, Jaffe ES, Chang Y et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999;93:4034-4043.
27. Bais C, Santomasso B, Coso O et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-89.
28. Nishi J, Arimura K, Utsunomiya A et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999;104:482-485.
29. Foss HD, Araujo I, Demel G et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997;183: 44-50.
30. Cohen T, Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741.
31. Sun X, Chang KC, Abruzzo LV et al. Epidermal growth factor receptor expression in follicular dendritic cells: A shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol 2003;34:835-840.
32. Gherardi RK, Bélec L, Fromont G et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy,Mprotein, and skin changes (POEMS) syndrome. Blood 1994;83:2587-2593.
33. Dinarello CA. Immunological and inflammatory functions of the interleukin- 1 family. Annu Rev Immunol 2009;27:519-550.
34. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-967.
35. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (anakinra). Mol Cancer Ther 2010;9:1485-1488.
36. Akula SM, Ford PW, Whitman AG et al. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus- infected human B cells. Blood 2005;105:4516-4522.
37. Zoeteweij JP, Moses AV, Rinderknecht AS et al. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. Blood 2001;97:2374-2380.
38. Herrada J, Cabanillas F, Rice L et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-662.
39. Bowne WB, Lewis JJ, Filippa DA et al. The management of unicentric and multicentric Castleman's disease: A report of 16 cases and a review of the literature. Cancer 1999;85:706-717.
40. Chronowski GM, Ha CS, Wilder RB et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92:670-676.
41. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001;66: 148-150.
42. Loi S, Goldstein D, Clezy K et al. Castleman's disease and HIV infection in Australia. HIV Med 2004;5:157-162.
43. Ogita M, Hoshino J, Sogawa Y et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007;68:171-176.
44. Repetto L, Jaiprakash MP, Selby PJ et al. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986;4:213-217.
45. Barbounis V, Efremidis A. A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Anticancer Res 1996;16:545-547.
46. Hudson TJ, Edlund MJ, Steffick DE et al. Epidemiology of regular prescribed opioid use: Results from a national, population-based survey. J Pain Symptom Manage 2008;36:280-288.
47. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008;18:321-329.
48. Friedrichs C, Neyts J, Gaspar G et al. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 2004;62:121-123.
49. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997;41:2754-2756.
50. Casper C, Nichols WG, Huang ML et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-1634.
51. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIVassociated multicentric Castleman disease. Blood 2004;103:4368-4369; author reply 4369.
52. Zietz C, Bogner JR, Goebel FD et al. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999;340:1923-1924.
53. Aaron L, Lidove O, Yousry C et al. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: The impact of highly active antiretroviral therapy. Clin Infect Dis 2002;35:880-882.
54. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009;4:16-21.
55. Oksenhendler E, Boulanger E, Galicier L et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336.
56. Feremans WW, Khodadadi E. Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. Eur J Haematol 1987;39:91.
57. Tamayo M, Gonzalez C, Majado MJ et al. Long-term complete remission after interferon treatment in a case of multicentric Castelman's disease. Am J Hematol 1995;49:359-360.
58. Kumari P, Schechter GP, Saini N et al. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis 2000;31:602-604.
59. Andrès E, Maloisel F. Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 2000;11:1613-1614.
60. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255-266.
61. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
62. Shannon E, Noveck R, Sandoval F et al. Thalidomide suppressed interleukin- 6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res 2007;150:275-280.
63. Miltenyi Z, Toth J, Gonda A et al. Successful immunomodulatory therapy in Castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res 2009;15:375-381.
64. Stary G, Kohrgruber N, Herneth AM et al. Complete regression of HIVassociated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 2008;22:1232-1234.
65. Marcelin AG, Aaron L, Mateus C et al. Rituximab therapy for HIVassociated Castleman disease. Blood 2003;102:2786-2788.
66. Gérard L, Bérezné A, Galicier L et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-3356.
67. Bower M, Powles T, Williams S et al. Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147:836-839.
68. Estephan FF, Elghetany MT, Berry M et al. Complete remission with anti- CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease. Cancer Invest 2005;23:191.
69. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005;78:302-305.
70. Hudnall SD, Chen T, Brown K et al. Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome. Arch Pathol Lab Med 2003;127:1034-1036.
71. Beck JT, Hsu SM, Wijdenes J et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602-605.
72. Nishimoto N, Sasai M, Shima Y et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
73. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005;28:221-230.
74. Van Rhee F, Fayad L, Voorhees P et al. Siltuximab, a novel anti-interleukin- 6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28:3701-3708.
75. Ahmed B, Tschen JA, Cohen PR et al. Cutaneous Castleman's disease responds to anti-interleukin-6 treatment. Mol Cancer Ther 2007;6:2386-2390.
76. Hess G, Wagner V, Kreft A et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006;134:544-545.
77. Sobas MA, Alonso Vence N, Dias Arias J et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome (MCD-POEMS variant). Ann Hematol 2010;89:217-219.
78. Rajkumar SV, Richardson PG, Hideshima T et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-39.
79. Kalliolias GD, Liossis SNC. The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic- onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008;17:349-359.
80. Galeotti C, Tran TA, Franchi-Abella S et al. IL-1 RA Agonist (anakinra) in the treatment of multifocal Castleman disease: Case report. J Pediatr Hematol Oncol 2008;30:920-924.
81. Medical News Today. 'Actemra(R)' - World's First Drug for Castleman's Disease - Launched in Japan. Available at http://www.medicalnewstoday.com/articles/26049.php, accessed March 8, 2011.
82. Vermeulen J, Qi M, Herring JB et al. A randomized, double-blind, placebo- controlled, study to assess siltuximab (CNTO-328, an anti-IL6) in patients with multicentric Castleman's disease [abstract TPS186]. Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4-8, 2010.
83. ClinicalTrials.gov. A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared to Best Supportive Care in Patients With Multicentric Castleman's Disease. Available at http://www.clinicaltrials.gov/ct2/show/NCT01024036, accessed March 8, 2011.
84. Summerfield GP, Taylor W, Bellingham AJ et al. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol 1983;36:1005-1011.
85. Frizzera G, Peterson BA, Bayrd ED et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3:1202-1216.
86. Weisenburger DD, Nathwani BN, Winberg CD et al. Multicentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases. Hum Pathol 1985;16:162-172.
87. Stanley MW, Frizzera G, Dehner LP. Castleman's disease, plasma-cell type. Diagnosis of central nervous system involvement by cerebrospinal fluid cytology. Acta Cytol 1986;30:481-486.
88. Donaghy M, Hall P, Gawler J et al. Peripheral neuropathy associated with Castleman's disease. J Neurol Sci 1989;89:253-267.
89. Pavlidis NA, Skopouli FN, Bai MC et al. A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease). Med Pediatr Oncol 1990;18:333-335.
90. Bordeleau L, Bredeson C, Markman S. 2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol 1995;91:668-670.
91. Colleoni GW, Duarte LC, Kerbauy FR et al. 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol 2003; 42:784-787.
92. Park JB, Hwang JH, Kim H et al. Castleman disease presenting with jaundice: Acase with the multicentric hyaline vascular variant. Korean J Intern Med 2007;22:113-117.
93. Seo HY, Kim EB, Kim JW et al. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 2009;41:104-107.
94. Lee JH, Kwon KA, Lee S et al. Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res 2010;34:e42-e45.
95. Rossi JF, Fegueux N, Calvet B et al. Alpha-interferon in angioimmunoblastic lymphadenopathy. Ann Intern Med 1988;109:512-513.
96. Pavlidis NA, Briassoulis E, Klouvas G et al. Is interferon-a an active agent in Castleman's disease? Ann Oncol 1992;3:85-86.
97. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS 2003;14:61-62.
98. Jung CP, Emmerich B, Goebel FD et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004;75:176-177.
99. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006;81:303-304.
100. Corbellino M, Bestetti G, Scalamogna C et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-3475.
101. Marrache F, Larroche C, Mémain N et al. Prolonged remission of HIVassociated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS 2003;17:1409-1410.
102. Abdou S, Salib H. An extra ordinary response of Castleman's disease to Rituximab. Blood 2004;104:49b-49b.
103. Gholam D, Vantelon JM, Al-Jijakli A et al. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 2003;82:766-768.
104. Kofteridis DP, Tzagarakis N, Mixaki I et al. Multicentric Castleman's disease: Prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient. AIDS 2004;18:585-586.
105. Newsom-Davis T, Bower M, Wildfire A et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 2004;45: 1939-1941.
106. Neuville S, Agbalika F, Rabian C et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 2005;79:337-339.
107. Casquero A, Barroso A, Fernàndez Guerrero ML et al. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 2006;85:185-187.
108. Ide M, Kawachi Y, Izumi Y et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006;76:119-123.
109. Fragasso A, Mannarella C, Ciancio A et al. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease. Leuk Lymphoma 2008;49:2224-2226.